150864-11-2

Upstream product

• 589-29-7 p-xylylene glycol 
• 18162-48-6 tert-butyldimethylsilyl chloride 

Downstream Products

• 152124-07-7 tert-Butyl-dimethyl-(4-tridecyloxymethyl-benzyloxy)-silane 
• 1026871-78-2 tert-Butyl-dimethyl-(4-tridec-2-ynyloxymethyl-benzyloxy)-silane 
• 152124-11-3 1-(tert-Butyldi-methylsilyloxymethyl)-4-(2-undecynyloxymethyl)benzene 
• 152124-15-7 tert-Butyl-dimethyl-(4-pentadec-2-ynyloxymethyl-benzyloxy)-silane 
• 152123-73-4 tert-Butyl-dimethyl-{4-[((Z)-tridec-2-enyl)oxymethyl]-benzyloxy}-silane 
• 152124-01-1 cis-1-(tert-Butyldimethylsilyloxymethyl)-4-(2-tridecenyloxymethyl)benzene 
• 152124-26-0 1-(tert-Butyldi-methylsilyloxymethyl)-4-(7-phenyl-2-heptynyloxymethyl) benzene 
• 680622-74-6 4-(13-azido-2,5,8,11-tetraoxatridecyl)-benzylalcohol 
• 571187-77-4 O⁶-[4-(13-amino-2,5,8,11-tetraoxa-tridecyl)-oxymethylbenzyl]guanine 
• 680622-75-7 O⁶-[4-(13-azido-2,5,8,11-tetraoxatridecyl)benzyl]guanine 
• 1025903-28-9 1-Iodomethyl-4-non-2-ynyloxymethyl-benzene 
• 1027660-67-8 (4-Non-2-ynyloxymethyl-phenyl)-methanol 
• 152124-09-9 1-Iodomethyl-4-tridecyloxymethyl-benzene 
• 152124-08-8 (4-Tridecyloxymethyl-phenyl)-methanol 

Relevant academic research and scientific papers

(Carboxyalkyl)benzyl propargyl ethers as selective inhibitors of leukocyte-type 12-lipoxygenases

A series of (carboxyalkyl)benzyl propargyl ethers was synthesized and tested as inhibitors of 12-lipoxygenase (12-LO) from porcine leukocyte cytosol. Optimum activity was displayed by 3-[4-[(2- tridecynyloxy)methyl]phenyl]propanoic acid. Altering the length of the alkyl side chain attached to the acetylenic group reduced activity. Changing the substitution pattern in the (carboxyalkyl)benzyl group from para to meta or ortho also reduced activity. Analogs in which the triple bond was replaced by a double bond or an allene displayed reduced activity, whereas fully saturated analogs were inactive. High concentrations (10 μM) of the most potent acetylenic (carboxylalkyl)benzyl ethers did not inhibit human platelet 12-LO, human neutrophil 5-LO, rabbit reticulocyte 15-LO, or soybean 15-LO. Thus, this class of compounds represents the first example of isoform specific LO inhibitors.

THERAPEUTIC AGENTS AND CONJUGATES THEREOF

The present disclosure provides a class of conjugates of general formula (X), a class of TLR9 agonist derivatives, such as formula (I), (XX), and (XXI), certain diastereomers of STING agonists, a class of STING agonist derivatives, such as formula (XXVIV), a class of heterocyclic compounds of general formula (II), a class of heterocyclic compounds of general formula (III), as defined herein. A1, A2, T, Z1, Z2, Z3, b1, and b2, in formula (X) are defined herein. The conjugate provides unique properties that are based upon the properties of the therapeutic agents that are part of the conjugate. Also provided are methods of synthesis and use of compounds.

ARYL ALIPHATIC ACIDS

Novel aryl aliphatic acids or derivatives thereof of the general formula R-(Cx-Cy)-(CmH2m)-G-C(R1)2-Ar-(CnH2n)-COOR2 are described which exhibit inhibiting activity against 12-lipoxygenase. The compounds are characterized by having a low level of toxicity. Also included are salts and esters of the aliphatic acids